The Prognostic Role of Apelin in the Assessment of Cardiac Outcomes in Patients with Chronic Kidney Disease: A Case-Control Study
| International Journal of Medical Science |
| © 2023 by SSRG - IJMS Journal |
| Volume 10 Issue 6 |
| Year of Publication : 2023 |
| Authors : Janet Ali, Rami A. Jarjour, Abdul-Fattah Abbas, Muhammed Imad Khayat |
10.14445/23939117/IJMS-V10I6P108
How to Cite?
Janet Ali, Rami A. Jarjour, Abdul-Fattah Abbas, Muhammed Imad Khayat, "The Prognostic Role of Apelin in the Assessment of Cardiac Outcomes in Patients with Chronic Kidney Disease: A Case-Control Study," SSRG International Journal of Medical Science, vol. 10, no. 6, pp. 48-55, 2023. Crossref, https://doi.org/10.14445/23939117/IJMS-V10I6P108
Abstract:
Chronic kidney disease is a complicated, multifaceted disorder with multiple complications. Limited studies have assessed the potential role of Apelin in the assessment of cardiac outcomes in patients with chronic kidney disease. Herein, we performed a prospective case-control study including 70 patients with CKD. Patients on chronic dialysis were excluded. Laboratory examinations, including serum Apelin levels, were performed. Moreover, the patients were monitored for 18 months. The mean value of apelin was lower in CKD patients than in the control group (378.86 pg/ml compared to 663.93 pg/ml, p<0.0001). Cardiovascular complications were more frequent in CKD patients than in the control group (38.6% as compared to 6.7%, respectively, p=0.017). Furthermore, serum apelin levels were lower in patients with CVD complications (317.3 ± 73.9 pg/ml, compared to 417.5 ±51.3 pg/ml, p<0.001). Multivariate regression analysis revealed that only Apelin levels were a significant predictor of CVD complications with a negative correlation (Odds ratio 0.96, 95%CI [0.95-0.99], p=0.001) Subsequently, we found that only apelin had a significant correlation with the occurrence of cardiovascular complications in patients with CKD. The lower the levels of apelin, the higher the incidence of cardiovascular complications.
Keywords:
Apelin, Chronic Kidney Disease, Cardiovascular disease, Prognosis.
References:
[1] Bogdan Ene-Iordache et al., “Chronic Kidney Disease and Cardiovascular Risk in Six Regions of the World (ISN-KDDC): A CrossSectional Study,” The Lancet Glob Health, vol. 4, no. 5, pp. e307–e319, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[2] Lisa M. Miller et al., “Cardiovascular Disease in End-Stage Renal Disease: The Challenge of Assessing and Managing Cardiac Disease in Dialysis Patients,” International Urology and Nephrology, vol. 42, pp. 1007–1014, 2010.
[CrossRef] [Google Scholar] [Publisher Link]
[3] Antonio Granata et al., “Cardiorenal Syndrome Type 4: From Chronic Kidney Disease to Cardiovascular Impairment,” European Journal of Internal Medicine, vol. 30, pp. 1–6, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[4] Giuseppe Enia et al., “Long-term CAPD Patients are Volume Expanded and Display More Severe Left Ventricular Hypertrophy than Haemodialysis Patients,” Nephrology Dialysis Transplantation, vol. 16, no. 7, pp. 1459–1464, 2001.
[CrossRef] [Google Scholar] [Publisher Link]
[5] Brian F. O’Dowd et al., “A Human Gene that Shows Identity with the Gene Encoding the Angiotensin Receptor is Located on Chromosome 11,” Gene, vol. 136, no. 1-2, pp. 355–360, 1993.
[CrossRef] [Google Scholar] [Publisher Link]
[6] Kazuhiko Tatemoto et al., “Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998.
[CrossRef] [Google Scholar] [Publisher Link]
[7] Ricardo Ladeiras-Lopes, João Ferreira-Martins, and Adelino F. Leite-Moreira, “The Apelinergic System: The Role Played in Human Physiology and Pathology and Potential Therapeutic Applications,” Arquivos Brasileiros de Cardiologia, vol. 90, pp. 343–349, 2008.
[CrossRef] [Google Scholar] [Publisher Link]
[8] Matthias J. Kleinz, Jeremy N. Skepper, and Anthony P. Davenport, “Immunocytochemical Localization of the Apelin Receptor, APJ, to Human Cardiomyocytes, Vascular Smooth Muscle and Endothelial Cells,” Regulatory Peptides, vol. 126, no. 3, pp. 233–240, 2005.
[CrossRef] [Google Scholar] [Publisher Link]
[9] I. Falcao-Pires, and A.F. Leite-Moreira, “Apelin: A Novel Neurohumoral Modulator of the Cardiovascular System: Pathophysiologic Importance and Potential Use as a Therapeutic Target,” Revista Portuguesa de Cardiologia, vol. 24, pp. 1263–1276, 2005.
[Google Scholar] [Publisher Link]
[10] Kazuhiko Tatemoto et al., “The Novel Peptide Apelin Lowers Blood Pressure via a Nitric Oxide-Dependent Mechanism,” Regulatory Peptides, vol. 99, no. 2-3, pp. 87–92, 2001.
[CrossRef] [Google Scholar] [Publisher Link]
[11] Sidath D Katugampola et al., “[125I]-(Pyr1 )Apelin-13 is a Novel Radioligand for Localizing the APJ Orphan Receptor in Human and Rat Tissues with Evidence for a Vasoconstrictor Role in Man,” British Journal of Pharmacology, vol. 132, no. 6, pp. 1255–1260, 2009.
[CrossRef] [Google Scholar] [Publisher Link]
[12] Istvan Szakodi et al., “Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility,” Circulation Research, vol. 91, pp. 434–440, 2002.
[CrossRef] [Google Scholar] [Publisher Link]
[13] Shahrad Taheri et al., “The Effects of Centrally Administered Apelin-13 on Food Intake, Water Intake and Pituitary Hormone Release in Rats,” Biochemical and Biophysical Research Communications, vol. 291, no. 5, pp. 1208–1212, 2002.
[CrossRef] [Google Scholar] [Publisher Link]
[14] Annette Hus-Citharel et al., “Effect of Apelin on Glomerular Hemodynamic Function in the Rat Kidney,” Kidney International, vol. 74, no. 4, pp. 486–494, 2008.
[CrossRef] [Google Scholar] [Publisher Link]
[15] Kwok Shiong Chong et al., “Plasma Concentrations of the Novel Peptide Apelin are Decreased in Patients with Chronic Heart Failure,” European Journal of Heart Failure, vol. 8, no. 4, pp. 355–360, 2006.
[CrossRef] [Google Scholar] [Publisher Link]
[16] Chen M Mary et al., “Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction,” Circulation, vol. 108, pp. 1432–1439, 2003.
[CrossRef] [Google Scholar] [Publisher Link]
[17] Peng-Fei Shan et al., “Apelin Attenuates the Osteoblastic Differentiation of Vascular Smooth Muscle Cells,” PLoS One, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[18] Ginimol Mathew, and Riaz Agha, “STROCSS 2021: Strengthening the Reporting of Cohort, Cross-Sectional and Case-Control Studies in Surgery,” International Journal of Surgery Open, vol. 96, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[19] Amal M. El-Shehaby et al., “Apelin: A Potential Link between Inflammation and Cardiovascular Disease in End Stage Renal Disease Patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 6, pp. 421–427, 2010.
[CrossRef] [Google Scholar] [Publisher Link]
[20] Carmine Zoccali et al.., “The Complexity of the Cardio-Renal Link: Taxonomy, Syndromes, and Diseases,” Kidney International Supplements, vol. 1, no. 1, pp. 2–5, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[21] Ana Paula Silva et al., “What Is the Role of Apelin Regarding Cardiovascular Risk and Progression of Renal Disease in Type 2 Diabetic Patients with Diabetic Nephropathy?,” Biomed Research International, vol. 2013, pp. 1-7, 2013.
[CrossRef] [Google Scholar] [Publisher Link]
[22] Jolanta Małyszko et al., “Apelin and Cardiac Function in Hemodialyzed Patients: Possible Relations?,” American Journal of Nephrology, vol. 26, no. 2, pp. 121–126, 2006.
[CrossRef] [Google Scholar] [Publisher Link]
[23] Jolanta Malyszko et al., “Type of Arteriovenous Fistula, NYHA Class and Apelin in Hemodialyzed Patients,” International Urology and Nephrology, vol. 43, pp. 185–190, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[24] A.G. Japp et al., “Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients with Chronic Heart Failure,” Circulation, vol. 121, pp. 1818–1827, 2010.
[CrossRef] [Google Scholar] [Publisher Link]
[25] Viviane O. Leal et al., “Apelin: A Peptide Involved in Cardiovascular Risk in Hemodialysis Patients?,” Renal Failure, vol. 34, no. 5, pp. 577–581, 2012.
[CrossRef] [Google Scholar] [Publisher Link]